Considering this observation and the fact that melanoma patients with COX-2-positive primary tumors bear a significantly higher risk of tumor recurrence [15], introduction of COX-2 inhibitors for primary adjuvant treatment of these patients seems obvious. Here, PTGS2 is linked to neoplasm.